New combo therapy targets tough lung cancer complication
NCT ID NCT07482605
First seen May 05, 2026 · Last updated May 06, 2026 · Updated 1 time
Summary
This study tests whether combining the drug furmonertinib with chest radiation can help control EGFR-positive lung adenocarcinoma that has spread to the lining of the lung, causing fluid buildup. About 63 adults will receive the treatment to see if it delays cancer growth. Researchers will also use blood tests to find which patients benefit most.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.